CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,202 enrolled
Drug / intervention
None (Observational study)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06147830
NCT06147830N/ACompleted

A Multinational Observational Longitudinal Study to Describe the Patient Characteristics, Health Care Interventions, and Health Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

AstraZeneca·observational·Posted Nov 28, 2023·Updated Nov 3, 2025

In Brief

An observational study evaluating None (Observational study) for Major Bleeding. Completed, enrolled 2,202 participants across 75 sites in 4 countries.

Detailed Summary

REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Bleeding
CountriesGermany, Japan, United Kingdom, United States
CollaboratorsParexel

Timeline

N/ACompletedFinished
202420252026
First PostedNov 28, 2023
Enrollment StartDec 4, 2023
Primary CompletionNov 30, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.6 years ago

Interventions

None (Observational study)other

Not Applicable since Observational Study